FGFR2 and cancer: MET signaling may promote cancer recurrence as well as insulin resistance and diabetes [51, 52]; the WNT pathway could be associated with adipocyte hyperplasia, diabetes, and metabolic disorders [53]; and FGFR2 transduction signaling also may play a role in obesity, adipocyte hyperplasia, and cancer [54, 55].